Previous Article | Next Article ![]()
Molecular and Cellular Biology, November 2003, p. 7667-7677, Vol. 23, No. 21
0270-7306/03/$08.00+0 DOI: 10.1128/MCB.23.21.7667-7677.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Program of Signal Transduction, Burnham Institute, La Jolla, California,2 Molecular Oncology Group, Lady Davis Institute for Medical Research,1 Departments of Medicine, Microbiology and Immunology, McGill University,3 Division of Hematology-Oncology, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Canada4
Received 28 April 2003/ Returned for modification 13 June 2003/ Accepted 22 July 2003
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
, as observed with thymocytes (29).
Activation of the receptor-associated ZAP-70 is accomplished by the phosphorylation of Tyr-493 of ZAP-70, a reaction catalyzed by the Src family kinase Lck (4, 26, 28, 36). Tyr-493 corresponds to the positive regulatory phosphorylation site in the activation loop in all protein kinases, except Csk. In contrast to Src family PTKs and many other kinases, ZAP-70 is unable to autophosphorylate at this site. However, once ZAP-70 has been activated by phosphorylation at Tyr-493, the kinase becomes able to autophosphorylate at a number of additional tyrosine residues, which subsequently function as docking sites for SH2 domain-containing enzymes or adapters, including Lck (13), Abl (30), Vav (22, 39), Cbl (15, 24, 25, 27), and PLC
1 (12, 32).
We have found that ZAP-70, in addition to being phosphorylated on tyrosine, is highly phosphorylated on serine. One of the targets of this phosphorylation was identified as Ser-520, located in the conserved SDVWS motif immediately downstream of the activation loop of ZAP-70. This phosphorylation site proved to be important for the normal function of ZAP-70 in TCR signaling and interleukin-2 gene activation.
| MATERIALS AND METHODS |
|---|
|
|
|---|
MAb (OKT3) was from Ortho Diagnostic Systems Inc. (Raritan, N.J.), anti-HA.11 MAb was from Bio/Can Scientific (Montreal, Canada), horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G (IgG) and goat anti-rabbit IgG were from Zymed (San Francisco, Calif.), anti-Lck MAb (3A5) and polyclonal anti-Lck (2102) were from Santa Cruz Biotechnology (Santa Cruz, Calif.), anti-human TCR-
was from BD Pharmingen (San Diego, Calif.), and agarose-conjugated goat anti-rabbit IgG and anti-mouse IgG were from Sigma (St. Louis, Mo.). The rabbit polyclonal antibodies against ZAP-70 were generated as previously described (8). Plasmids and site-directed mutagenesis. The expression plasmids for ZAP-70 in pEF/HA and Lck in pEF-neo have been described previously (9). Luciferase reporter plasmids were described previously (1, 18, 21). Renilla luciferase as well as the Dual-Luciferase reporter assay system kit were purchased from Promega (Madison, Wis.). Site-directed mutagenesis was done using the QuikChange kit (Stratagene, La Jolla, Calif.), following the manufacturer's instructions. The cDNAs encoding myristylated versions of ZAP-70 were generated by addition of nucleotides encoding the first 16 amino acids from Lck upstream of the hemagglutinin (HA) tag.
Cells and transfections. The Jurkat human T leukemia cell line, Jurkat TAg (a clone stably transfected with simian virus 40 large T antigen), and the ZAP-70-deficient Jurkat clone P116 (38) were kept at logarithmic growth in RPMI 1640 with L-glutamine, containing 5% fetal calf serum and antibiotics. Jurkat TAg cells were grown in the presence of 0.5 mg of G418/ml. COS cells were grown in Dulbecco's modified Eagle medium with 5% fetal calf serum and antibiotics.
COS cells were transfected at 106 cells per sample by lipofection with 5 to 10 µg of plasmid DNA as previously described (8, 9). Jurkat cells were transfected with 10 to 30 µg of plasmid DNA at 107 cells/sample by electroporation at 280 V, 950 µF, in a Gene Pulser II (Bio-Rad). Cells were used 48 h after transfection.
Immunoprecipitation, gel electrophoresis, and immunoblotting. Immunoprecipitations were carried out as before (8-11). Proteins were resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis on 10 to 12% gels, transferred to nitrocellulose membranes, and immunoblotted with anti-ZAP-70 MAb (1:3,000), anti-HA MAb (10 µg/ml), or 4G10 antiphosphotyrosine (anti-pTyr) MAb (1:5,000). The blots were developed by the enhanced chemiluminescence technique (ECL kit; Amersham) according to the manufacturer's instructions.
Metabolic 32P labeling, tryptic peptide mapping, and phosphoamino acid analysis. Transfected cells were phosphate starved in phosphate-free RPMI 1640 medium containing 20 mM HEPES for 1 h at 37°C and labeled for 4 h with 4 mCi of 32Pi/ml in phosphate-free medium. Cells were incubated with 5 µg of OKT3 MAb/ml on ice for 15 min, washed, and incubated with 10 µg of goat anti-mouse IgG/ml at 37°C (for the times indicated in the figures) or treated with 0.5 µM okadaic acid for 1 h at 37°C. The cells were lysed under denaturing conditions (11), and HA-tagged ZAP-70 was immunoprecipitated. Proteins were resolved by SDS-PAGE, transferred to nitrocellulose filters, localized by autoradiography, and excised. Tryptic peptide mapping was carried out by the method of Luo and colleagues (23) as members of our group have done before (1, 3, 9-11, 33). Briefly, the filter pieces were blocked with polyvinylpyrrolidone 360, washed, and incubated with two additions of 10 µg of tosylphenylalanyl chloromethyl ketone-treated trypsin in 50 mM ammonium bicarbonate. The released phosphopeptides were lyophilized twice and then separated by electrophoresis on cellulose thin-layer plates (Merck, Darstadt, Germany) at 1,000 V in pH 1.9 buffer for 27 min, followed by ascending chromatography in n-butanol-pyridine-acetic acid-water (75:50:15:60) for 16 h. The resulting peptide maps were then dried and exposed to film.
For secondary digests, phosphopeptides 1, 2, and 3 were eluted from the phosphopeptide map of wild-type ZAP-70 and divided into three samples. A first sample was redigested with trypsin to ensure that the first digest was complete, and a second sample was digested with 10 µg of chymotrypsin. The third sample was used for phosphoamino acid analysis (see below). Sensitivity to chymotrypsin was assessed by comigration of the tryptic and chymotryptic peptides originating from peptides 1 and 3. Peptide 2 was processed as described in Results. Phosphoamino acid analysis was performed as described previously (7). Briefly, the 32P-labeled proteins or peptides were eluted from either polyvinylidene difluoride membranes or from peptide maps and hydrolyzed by incubation in 6 N HCl for 2 h at 110°C. The material was lyophilized and separated by electrophoresis in pH 1.9-pH 3.5 buffer (1:1 ratio [7]). 32P-labeled amino acids were detected by autoradiography, and identified by comigration of standard phosphoamino acids that were added to each sample and detected by ninhydrin staining.
Manual Edman degradation. 32P-labeled phosphopeptides were extracted from the thin-layer plate and dissolved in 20 µl of water, and 2 µl was taken as starting material. Twenty microliters of 5% phenyl isothiocyanate in pyridine was added and incubated for 30 min at 45°C. The sample was extracted at room temperature with heptane-ethyl acetate (10:1) and then with heptane-ethyl acetate (2:1). The final aqueous phase was frozen and lyophilized. The sample was cleaved in 50 µl of trifluoroacetic acid, incubated for 10 min at 45°C, and lyophilized. The residue was resuspended in 18 µl of water, and 2 µl was kept as first cycle product. The volume was then restored to 20 µl, and the whole procedure was repeated up to six times. The reaction products of each cycle were analyzed by thin-layer electrophoresis for 25 min at 1 kV at pH 1.9 followed by autoradiography with free 32Pi as a marker. In this protocol, the release of free 32Pi results from ß elimination during cyclization and indicates the presence of a PSer or phosphothreonine (PThr) residue. In contrast, PTyr is stable to cyclization and is released as the anilinothiazolinone derivative of PTyr, which can be converted to the phenylthiohydantoin of PTyr by incubation of the reaction products in 0.1 N HCl for 20 min at 80°C and can be detected as a dark spot when the thin-layer chromatography plate is examined under UV light or stained with ninhydrin.
Kinase assays.
Immune complex kinase assays were carried out by incubation of immunoprecipitated ZAP-70 in a solution containing 25 µl of 10 mM Tris-HCl (pH 7.5), 10 mM MgC12, 10 mM MnCl2, 0.1% Triton X-100, with 1 µM ATP and 10 µCi of [
-32P]ATP for 20 min at 30°C. The reaction was stopped by adding SDS sample buffer and heating at 95°C for 2 min. The phosphorylation of proteins was analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography. Incorporation of 32P was quantitated by liquid scintillation in a ß-counter.
Luciferase assays.
These assays were carried out essentially as described previously (1, 21). Briefly, ZAP-70-deficient P116 cells were transiently cotransfected with empty vector, ZAP-70 wild type, or mutant constructs, together with 0.5 µg of Renilla luciferase plasmid and 5 µg of reporter plasmid. Twenty-four hours later, cells were stimulated with 2 µg of anti-CD3
MAb/ml plus 4 µg of goat anti-mouse antibody/ml alone or with 50 ng of phorbol myristate acetate (PMA)/ml and for maximum activity with 50 ng of PMA/ml plus 1.5 µM ionomycin for 6 h at 37°C. Cells were lysed, and luciferase activity was determined with a luminometer (EG&G Berthold Lumat LB 9507) according to the instructions for the Dual-Luciferase reporter assay system (Promega). Luciferase activities were normalized for transfection efficiency using the Renilla luciferase activity, and results are expressed as a percentage of the activity induced by PMA plus ionomycin. Each shown value is an average from triplicate determinations.
Confocal microscopy. Immunofluorescence staining was done as before (1, 17, 37). Briefly, cells were washed in phosphate-buffered saline and fixed in freshly made 3.7% formaldehyde. Fixed cells were permeabilized with 0.1% saponin in phosphate-buffered saline, blocked in 2.5% normal goat serum in 0.1% saponin in phosphate-buffered saline for 30 min at room temperature, and then incubated with primary and secondary antibodies diluted in the same buffer for 1 h each at room temperature. After three washes with phosphate-buffered saline, the cells were mounted onto glass slides and viewed under a confocal laser scanning microscopy MRC-1024 (Bio-Rad). A differential interference contrast image was also taken of most cells.
Isolation of lipid rafts. Detergent-soluble and -insoluble fractions of transfected Jurkat cells were prepared by lysing 2 x 107 cells in a solution containing 1 ml of 1% Triton X-100, 25 mM 2-(N-morpholino)ethanesulfonic acid (pH 6.5), 150 mM NaCl, 5 mM EDTA, 30 mM sodium pyrophosphate, 1 mM Na3VO4 and 10 µg of leupeptin and aprotinin/ml for 20 min on ice and homogenized 10 to 15 times with a Dounce homogenizer. Samples were centrifuged at 1,000 x g for 10 min at 4°C. The supernatants were collected and mixed in 1 ml of lysis buffer containing 80% sucrose, transferred to ultracentrifuge tubes, and overlaid with 2 ml of lysis buffer containing 30% sucrose and 1 ml of buffer with 5% sucrose. Samples were centrifuged at 200,000 x g for 16 to 18 h at 4°C. Twelve fractions of 0.4 ml were collected from the top of the gradient. Fractions 2 to 4 and 8 to 12 were combined and referred to as Triton-insoluble glycolipid-enriched membranes (lipid rafts) and Triton-soluble fractions, respectively.
Subcellular fractionation. Jurkat cells (108) were suspended in a solution containing 1 ml of 20 mM Tricine (pH 7.8), 250 mM sucrose, 1 mM EDTA, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, and 1 µg of aprotinin/ml, homogenized 15 times with a Dounce homogenizer, and centrifuged at 1,000 x g for 10 min at 4°C. The supernatant was then centrifuged at 368,000 x g for 1 h at 4°C. The supernatant of this centrifugation is referred to as cytosol. Plasma membrane fractions were obtained by centrifugation (84,000 x g for 35 min at 4°C) of 1.5 ml of the postnuclear supernatant overlaid with homogenization buffer containing 30% Percoll. The opaque material at the interface was collected. The proteins from each fraction were precipitated by trichloroacetic acid in the presence of 20 µg of bovine serum albumin as a carrier, and the precipitate was washed with ice-cold ethanol and dissolved in SDS sample buffer.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
ZAP-70-S520A has an impaired ability to autophosphorylate. To begin the process of determining whether phosphorylation of ZAP-70 at Ser-520 plays any role in the regulation or function of ZAP-70, we first expressed the Ser-to-Ala mutants in COS cells alone or together with the Src family PTK Lck, the upstream activator of ZAP-70 in T cells (4, 5, 28, 36). Subsequently, the expressed ZAP-70 was immunoprecipitated and analyzed for kinase activity by autophosphorylation and for PTyr content by immunoblotting. As shown in Fig. 4A, unmutated ZAP-70 and the ZAP-70-S524A mutant were phosphorylated on tyrosine and readily autophosphorylated in vitro. In contrast, ZAP-70-S520A and ZAP-70-SSAA did not contain PTyr and had little kinase activity, despite being expressed at very similar levels. A negative control, the kinase-inactive ZAP-70-K369S mutant, behaved like the S520A and SSAA mutants. Coexpression of Lck (Fig. 4B) resulted in some tyrosine phosphorylation of all ZAP-70 constructs but only a modest increase in the kinase activity of the S520A and SSAA mutant ZAP-70s, despite levels of PTyr-content in these proteins similar to that in the unmutated ZAP-70. As expected, inactive or "kinase-dead" ZAP-70-K369S remained inactive. When the ZAP-70 constructs were expressed in Jurkat TAg cells, which express endogenous Lck, the catalytic activity of ZAP-70-S520A was also found to be very low (Fig. 5). No activation was observed after anti-CD3 stimulation of the cells, and even pervanadate had only a small effect on this mutant. Taken together, these experiments demonstrate that mutation of Ser-520 impaired ZAP-70 activation by Src family kinases.
|
|
|
.
To exclude the possibility that mutation of Ser-520 had more global effects on the folding or function of ZAP-70, we tested whether ZAP-70-S520A could still be recruited and bind phosphorylated TCR-
. COS-18 cells, which stably express a chimeric CD8
/TCR-
protein (5), were transfected with ZAP-70 constructs, and CD8
/TCR-
was immunoprecipitated and analyzed for bound ZAP-70. These experiments did not reveal any differences between constructs (not shown). This was not surprising, given that Ser-520 is in the catalytic domain of ZAP-70, which is not required for interaction of the tandem SH2 domains in the N terminus of ZAP-70 with phospho-ITAMs. It should also be noted that all ZAP-70 mutants were expressed at similar levels, suggesting that they all folded properly in cells. ZAP-70-S520A is not enriched at the plasma membrane. It has been reported that ZAP-70 is enriched at the plasma membrane in resting T cells in a manner that is independent of its SH2 domains but requires an intact kinase domain (19). Indeed, unmutated ZAP-70 was found to be enriched at the plasma membrane when expressed in Jurkat T cells, stained with anti-HA MAbs, and viewed under a confocal microscope (Fig. 7A). ZAP-70-S524A had a similar subcellular localization (not shown). In contrast, the S520A mutant displayed a more diffuse distribution throughout the cytosol (Fig. 7A). This result was obtained in many independent experiments and indicates that the S520A mutation impaired the normal targeting of ZAP-70 to docking sites at the plasma membrane, an event that presumably prepares the kinase for rapid mobilization upon TCR ligation (19, 34).
|
|
| DISCUSSION |
|---|
|
|
|---|
A key event in the activation of most kinases is the phosphorylation of one or several amino acid residues in their "activation loop," a flexible protrusion that participates in blocking substrate access in its unphosphorylated state but swings out and stabilizes an active conformation of the catalytic domain upon phosphorylation. In ZAP-70 the critical amino acid residue in this loop is Tyr-493 (4). The serine phosphorylation site that we have identified, Ser-520, is only 27 residues downstream of Tyr-493 and lies at the edge of the catalytic cleft. Ser-520 lies in a sequence motif (S520DVWS), which is well conserved in the beginning of subdomain IX of almost all protein kinases. Interestingly, the Src family PTK Blk is unique among kinases in that the serine corresponding to Ser-520 in ZAP-70 is replaced by an alanine, as in our ZAP-70-S520A mutant. This supports our notion that the hydroxyl group of Ser-520 is not necessary for proper folding of the kinase domain.
It is unclear at this point whether Ser-520 phosphorylation is constitutive or is inducible by TCR stimulation. Since the experiments leading to the identification of this site were conducted with resting Jurkat cells, we speculate that Ser-520 is phosphorylated prior to receptor engagement. Unfortunately, comparative phosphopeptide mapping of material isolated from different samples (here resting versus activated cells) is semiquantitative at best. Until we develop a reagent capable of detecting the phosphorylated form of Ser-520, it will be difficult to ascertain the inducible nature of Ser-520 phosphorylation.
Our data suggest that phosphorylation of ZAP-70 at Ser-520 may be involved in localizing the kinase to a submembranous location from which it can be rapidly recruited and activated following receptor ligation. Indeed, experiments with Jurkat T cells indicate that ZAP-70 activation occurs within seconds of TCR engagement. We speculate that prior membrane attachment of ZAP-70, perhaps through Ser-520, allows this nearly instantaneous activation. Such a mechanism may have evolved with the need for ZAP-70 to interact with phosphorylated ITAMs before the phosphorylated tyrosines of the motif are dephosphorylated by pTyr phosphatases, such as CD45 (16) or SHP-1 (32). It is also possible that Ser-520-mediated membrane localization allows ZAP-70 to compete more efficiently with other SH2-containing molecules for ITAM binding.
We contend that the primary role of Ser-520 phosphorylation may be to target the enzyme to the membrane, rather than merely activating ZAP-70. This possibility is supported by our finding that a forced plasma membrane and lipid raft location improves the ability of the mutant ZAP-70-S520A to mediate TCR signaling. This putative role of Ser-520 phosphorylation is in agreement with the earlier finding that ZAP-70 is enriched in the submembranous space of resting T cells in a kinase domain-dependent, but SH2-independent, manner (19). Phosphorylation at Ser-520 may promote binding to another cellular protein at the plasma membrane, which then serves as an anchor in this location. A possible candidate would be a member of the 14-3-3 family of proteins, which bind other proteins in a serine phosphorylation-dependent manner. It is also possible that phosphorylation of Ser-520 promotes the adoption of the enzymatically active conformation of ZAP-70, analogous with the "priming" phosphorylation that protein kinase C and many kinases require for subsequent activation by a variety of mechanisms. This might explain why the S520A-mutated ZAP-70 has a lower enzymatic activity than the wild-type enzyme in vitro.
Finally, it should be noted that we have identified only one site of serine phosphorylation in ZAP-70 and that several additional sites presumably remain to be recognized. A recent study showed that the Erk2 MAP kinase can phosphorylate and activate Syk (40). Since MAP kinases are proline-directed kinases, we find it very unlikely that Ser-520 is the site targeted by Erk2. There are several serine and threonine residues followed by prolines in Syk and ZAP-70 that constitute much more likely candidate sites for Erk2, such as Thr-293, Ser-301, and Ser-317, all of which lie close to important regulatory tyrosine residues. We also detected the presence of PSer in several other peptides in our tryptic peptide maps of metabolically labeled ZAP-70. It remains to be determined how many of these sites have a regulatory influence on ZAP-70, what aspects of ZAP-70 function they affect, and which Ser/Thr kinases phosphorylate these sites.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Arpaia, E., M. Shahar, H. Dadi, A. Cohen, and C. M. Roifman. 1994. Defective T cell receptor signaling and CD8+ thymic selection in humans lacking ZAP-70 kinase. Cell 76:947-958.[CrossRef][Medline]
3. Bottini, N., L. Stefanini, S. Williams, A. Alonso, J. Merlo, T. Jascur, R. T. Abraham, C. Couture, and T. Mustelin. 2002. Activation of ZAP-70 through specific dephosphorylation at the inhibitory Tyr-292 by the low molecular weight phosphotyrosine phosphatase (LMPTP). J. Biol. Chem. 277:24220-24224.
4. Chan, A. C., M. Dalton, R. Johnson, G. H. Kong, T. Wang, R. Thoma, and T. Kurosaki. 1995. Activation of ZAP-70 kinase activity by phosphorylation of tyrosine 493 is required for lymphocyte antigen receptor function. EMBO J. 14:2499-2508.[Medline]
5. Chan, A. C., M. Iwashima, C. W. Turck, and A. Weiss. 1992. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR
chain. Cell 71:649-662.[CrossRef][Medline]
6. Chu, D. H., C. T. Morita, and A. Weiss. 1998. The Syk family of protein tyrosine kinases in T-cell activation and development. Immunol. Rev. 165:167-180.[CrossRef][Medline]
7. Cooper, J. A., B. M. Sefton, and T. Hunter. 1983. Detection and quantitation of phosphotyrosine in proteins. Methods Enzymol. 99:387-402.[Medline]
8. Couture, C., G. Baier, A. Altman, and T. Mustelin. 1994. p56lck-independent activation and tyrosine phosphorylation of p72syk by T-cell antigen receptor/CD3 stimulation. Proc. Natl. Acad. Sci. USA 91:5301-5305.
9. Couture, C., G. Baier, C. Oetken, S. Williams, D. Telford, A. Marie-Cardine, G. Baier-Bitterlich, S. Fischer, P. Burn, A. Altman, and T. Mustelin. 1994. Activation of p56lck by p72syk through physical interaction and N-terminal tyrosine phosphorylation. Mol. Cell. Biol. 14:5249-5258.
10. Couture, C., M. Deckert, S. Williams, F. Otero Russo, A. Altman, and T. Mustelin. 1996. Identification of the site in the Syk protein tyrosine kinase that binds the SH2 domain of Lck. J. Biol. Chem. 271:24294-24299.
11. Couture, C., Z. Songyang, T. Jascur, S. Williams, P. Tailor, L. C. Cantley, and T. Mustelin. 1996. Regulation of the Lck SH2 domain by tyrosine phosphorylation. J. Biol. Chem. 271:24880-24884.
12. Di Bartolo, V., D. Mege, V. Germain, M. Pelosi, E. Dufour, F. Michel, G. Magistrelli, A. Isacchi, and O. Acuto. 1999. Tyrosine 319, a newly identified phosphorylation site of ZAP-70, plays a critical role in T cell antigen receptor signaling. J. Biol. Chem. 274:6285-6294.
13. Duplay, P., M. Thome, F. Herve, and O. Acuto. 1994. p56lck interacts via its src homology 2 domain with the ZAP-70 kinase. J. Exp. Med. 179:1163-1172.
14. Elder, M. E., D. Lin, J. Clever, A. C. Chan, T. J. Hope, A. Weiss, and T. G. Parslow. 1994. Human severe combined immunodeficiency due to a defect in ZAP, a T cell tyrosine kinase. Science 264:1596-1599.
15. Fournel, M., D. Davidson, R. Weil, and A. Veillette. 1996. Association of tyrosine protein kinase ZAP-70 with the protooncogene product p120c-cbl in T lymphocytes. J. Exp. Med. 183:301-306.
16. Furukawa, T., M. Itoh, N. X. Krueger, M. Streuli, and H. Saito. 1994. Specific interaction of the CD45 protein-tyrosine phosphatase with tyrosine-phosphorylated CD3
chain. Proc. Natl. Acad. Sci. USA 91:10928-10932.
17. Gjörloff-Wingren, A., M. Saxena, S. Han, X. Wang, A. Alonso, M. Renedo, P. Oh, S. Williams, J. Schnitzer, and T. Mustelin. 2000. Subcellular localization of intracellular protein tyrosine phosphatases in T cells. Eur. J. Immunol. 30:2412-2421.[CrossRef][Medline]
18. Hatada, M. H., X. Lu, E. R. Laird, J. Green, J. P. Morgenstern, M. Lou, C. S. Marr, T. B. Philips, M. K. Ram, K. Teriault, M. J. Zoller, and J. L. Kavas. 1995. Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor. Nature 376:32-38.[CrossRef]
19. Huby, R. D., M. Iwashima, A. Weiss, and S. C. Ley. 1997. ZAP-70 protein tyrosine kinase is constitutively targeted to the T cell cortex independently of its SH2 domains. J. Cell Biol. 137:1639-1649.
20. Isakov, N., R. L. Wange, W. H. Burgess, J. D. Watts, R. Aebersold, and L. E. Samelson. 1995. ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: the tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity. J. Exp. Med. 181:375-380.
21. Jascur, T., J. Gilman, and T. Mustelin. 1997. Involvement of phosphatidylinositol 3-kinase in NFAT activation in T cells. J. Biol. Chem. 272:14483-14488.
22. Katzav, S., M. Sutherland, G. Packham, T. Yi, and A. Weiss. 1994. The protein tyrosine kinase ZAP-70 can associate with the SH2 domain of proto-Vav. J. Biol. Chem. 269:32579-32585.
23. Luo, K., T. R. Hurley, and B. M. Sefton. 1990. Transfer of proteins to membranes facilitates both cyanogen bromide cleavage and two-dimensional proteolytic mapping. Oncogene 5:921-923.[Medline]
24. Lupher, M. L., Jr., K. A. Reedquist, S. Miyake, W. Y. Langdon, and H. Band. 1996. A novel phosphotyrosine-binding domain in the N-terminal transforming region of Cbl interacts directly and selectively with ZAP-70 in T cells. J. Biol. Chem. 271:24063-24068.
25. Lupher, M. L., Jr., Z. Songyang, S. E. Shoelson, L. C. Cantley, and H. Band. 1997. The Cbl phosphotyrosine-binding domain selects a D(N/D)XpY motif and binds to the Tyr292 negative regulatory phosphorylation site of ZAP-70. J. Biol. Chem. 272:33140-33244.
26. Mege, D., V. Di Bartolo, V. Germain, L. Tuosto, F. Michel, and O. Acuto. 1996. Mutation of tyrosines 492/493 in the kinase domain of ZAP-70 affects multiple T-cell receptor signaling pathways. J. Biol. Chem. 271:32644-32652.
27. Meng, W., S. Sawasdikosol, S. J. Burakoff, and M. J. Eck. 1999. Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase. Nature 398:84-90.[CrossRef][Medline]
28. Mustelin, T., R. T. Abraham, C. E. Rudd, A. Alonso, and J. J. Merlo. 2002. Protein tyrosine phosphorylation in T cell signaling. Front. Biosci. 7:918-969.[CrossRef]
29. Negishi, I., N. Motoyama, K. Nakayama, K. Nakayama, S. Senju, S. Hatakeyama, Q. Zhang, A. C. Chan, and D. Y. Loh. 1995. Essential role for ZAP-70 in both positive and negative selection of thymocytes. Nature 376:435-438.[CrossRef][Medline]
30. Neumeister, E. N., Y. Zhu, S. Richard, C. Terhorst, A. C. Chan, and A. S. Shaw. 1995. Binding of ZAP-70 to phosphorylated T-cell receptor
and
enhances its autophosphorylation and generates specific binding sites for SH2 domain-containing proteins. Mol. Cell. Biol. 15:3171-3178.[Abstract]
31. Pelosi, M., V. Di Bartolo, V. Mounier, D. Mege, J. M. Pascussi, E. Dufour, A. Blondel, and O. Acuto. 1999. Tyrosine 319 in the interdomain B of ZAP-70 is a binding site for the Src homology 2 domain of Lck. J. Biol. Chem. 274:14229-14237.
32. Perez-Villar, J. J., G. S. Whitney, M. A. Bowen, D. H. Hewgill, A. A. Aruffo, and S. B. Kanner. 1999. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol. Cell. Biol. 19:2903-2912.
33. Saxena, M., S. Williams, K. Taskén, and T. Mustelin. 1999. Crosstalk between cAMP-dependent kinase and MAP kinase through hematopoietic protein tyrosine phosphatase (HePTP). Nat. Cell Biol. 1:305-310.[CrossRef][Medline]
34. Sloan-Lancaster, J., J. Presley, J. Ellenberg, T. Yamazaki, J. Lippincott-Schwartz, and L. E. Samelson. 1998. ZAP-70 association with T cell receptor
(TCR
): fluorescence imaging of dynamic changes upon cellular stimulation. J. Cell Biol. 143:613-624.
35. Vang, T., V. Sundvold, F. O. Levy, B. S. Skålhegg, V. Hansson, T. Mustelin, and K. Tasken. 2001. Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J. Exp. Med. 193:497-507.
36. van Oers, N. S., N. Killeen, and A. Weiss. 1996. Lck regulates the tyrosine phosphorylation of the T cell receptor subunits and ZAP-70 in murine thymocytes. J. Exp. Med. 183:1053-1062.
37. Wang, X., H. Huynh, A. Gjörloff-Wingren, E. Monosov, M. Stridsberg, M. Fukuda, and T. Mustelin. 2002. Enlargement of secretory vesicles by protein tyrosine phosphatase PTP-MEG2 in RBL mast cells and Jurkat T cells. J. Immunol. 168:4612-4619.
38. Williams, B. L., K. L. Schreiber, W. Zhang, R. Wange, L. E. Samelson, P. J. Leibson, P. J. Leibson, and R. T. Abraham. 1998. Genetic evidence for differential coupling of Syk family kinases to the T-cell receptor: reconstitution studies in a ZAP-70-deficient Jurkat T-cell line. Mol. Cell. Biol. 18:1388-1399.
39. Wu, J., Q. Zhao, T. Kurosaki, and A. Weiss. 1997. The Vav binding site (Y315) in ZAP-70 is critical for antigen receptor-mediated signal transduction. J. Exp. Med. 185:1877-1882.
40. Xu, R., R. Seger, and I. Pecht. 1999. Cutting edge: extracellular signal-regulated kinase activates Syk: a new potential feedback regulation of Fc
receptor signaling. J. Immunol. 163:1110-1114.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|